The myth of the superiority of concurrent combined treatments for anxiety disorders

Clinical Psychology: Science and Practice

Volumn 17, Issue 2, 2010, Pages 107-111

  Pontoski, Kristin E ^a   Heimberg, Richard G ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Anxiety disorders; Attribution; Cognitive behavioral therapy; Combination therapy; Pharmacotherapy; Psychoeducation

Indexed keywords

EID: 77954588354     PISSN: 09695893     EISSN: 14682850     Source Type: Journal    
DOI: 10.1111/j.1468-2850.2010.01200.x     Document Type: Note

References (26)

1. Diagnostic and statistical manual of mental disorders 1994, 4th ed, Washington, DC, Author
2. Başoglu M, Marks I M, Kiliç C, Brewin C R. Alprazolam and exposure for panic disorder with agoraphobia attribution of improvement to medication predicts subsequent relapse. British Journal of Psychiatry 1994, 164:652-659.
3. Blanco C, Heimberg R G, Schneier F R, Fresco D M, Chen H, Turk C L. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy and their combination for social anxiety disorder. Archives of General Psychiatry 2010, 67:286-295.
4. Chavira D A, Stein M B, Roy-Byrne P. Managing anxiety in primary care. Oxford handbook of anxiety and related disorders 2009, 512-522. Antony M M, Stein M B, In, Eds, pp, New York, Oxford University Press
5. Craske M G, Golinelli D, Stein M B, Roy-Byrne P, Bystritsky A, Sherbourne C. Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting? Psychological Medicine 2005, 35:1645-1654.
6. Davidson J R, Foa E B, Huppert J D, Keefe F J, Franklin M E, Compton J S. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry 2004, 61:1005-1013.
7. Deacon B J, Abramowitz J S. Patients' perceptions of pharmacological and cognitive-behavioral treatments for anxiety disorders. Behavior Therapy 2005, 36:139-145.
8. Foa E B, Franklin M E, Moser J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination? Biological Psychiatry 2002, 52:987-997.
9. Gosselin P, Ladouceur R, Morin C M, Dugas M J, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy. Journal of Consulting and Clinical Psychology 2006, 74:908-919.
10. Guastella A J, Howard A L, Dadds M R, Mitchell P, Carson D S. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009, 34:917-923.
11. Haug T T, Blomhoff S, Hellstrøm K, Holme I, Humble M, Madsbu H P. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. British Journal of Psychiatry 2003, 182:312-318.
12. Hazlett-Stevens H, Craske M G, Roy-Byrne E E, Sherbourne C D, Stein M B, Bystritsky A. Predictors of willingness to consider medication and psychosocial treatment for panic disorder in primary care. General Hospital Psychiatry 2002, 24:316-321.
13. Heimberg R G. Cognitive-behavioral therapy for social anxiety disorder: Current status and future directions. Biological Psychiatry 2002, 51:101-108.
14. Huppert J, Franklin M, Foa E. Study refusal and exclusion from a randomized treatment study of generalized social phobia. Journal of Anxiety Disorders 2003, 17:683-693.
15. Kim Y W, Lee S-H, Choi T K, Suh S Y, Kim B, Kim C M. Effectiveness of mindfulness-based cognitive therapy as an adjunct to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depression and Anxiety 2009, 26:601-606.
16. Ma S H, Teasdale J D. Mindfulness-based cognitive therapy for depression: Replication and exploration of differential relapse-prevention effects. Journal of Consulting and Clinical Psychology 2004, 72:31-40.
17. Otto M W, Basden S L, Leyro T M, McHugh R K, Hofmann S G. Clinical perspectives on the combination of d-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectrums 2007, 12:51-56.
18. Otto M W, McHugh R K, Kantak K M. Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: Medication effects, glucocorticoids, and attenuated treatment outcomes. Clinical Psychology: Science and Practice 2010, 17:91-103.
19. Otto M W, Pollack M H, Sachs G S, Reiter S R, Meltzer-Brody S, Rosenbaum J F. Discontinuation of benzodiazepine treatment: Efficacy of cognitive-behavioral therapy for patients with panic disorder. American Journal of Psychiatry 1993, 150:1485-1490.
20. Otto M W, Smits J A J, Reese H E. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: Review and analysis. Clinical Psychology: Science and Practice 2005, 12:72-86.
21. Powers M B, Smits J A J, Whitley D, Bystritsky A, Telch M J. The effect of attributional processes concerning medication taking on return of fear. Journal of Consulting and Clinical Psychology 2008, 76:478-490.
22. Segal Z V, Williams J M G, Teasdale J D. Mindfulness-based cognitive therapy for depression: A new approach to preventing relapse 2002, New York, Guilford Press
23. Teasdale J D, Segal Z V, Williams J M G, Ridgeway V A, Soulsby J M, Lau M A. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Journal of Consulting and Clinical Psychology 2000, 68:615-623.
24. Walkup J, Albano A M, Piacentini J, Birmaher B, Compton S, Sherrill J. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. New England Journal of Medicine 2008, 359:2753-2766.
25. Wisniewski S R, Fava M, Trivedi M H, Thase M E, Warden D, Niederehe G. Acceptability of second-step treatments to depressed outpatients: A STAR*D report. American Journal of Psychiatry 2007, 164:753-760.
26. Yook K, Lee S-H, Ryu M, Kim K-H, Choi T K, Suh S Y. Usefulness of mindfulness-based cognitive therapy for treating insomnia in patients with anxiety disorders: A pilot study. Journal of Nervous and Mental Disease 2008, 196:501-503.